Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 19/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3645309 | 0.84 | GRM5 (0.60) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL4256707 | 0.77 | GRM5 (0.43) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL27790873 | 0.77 | GRM5 (0.47) | GRM5CYP1A2CYP3A4 | |
| SCHEMBL4258258 | 0.76 | GRM5 (0.43) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL4256726 | 0.76 | GRM5 (0.47) | GRM5 | |
| SCHEMBL4255281 | 0.74 | GRM5 (0.44) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL3642219 | 0.74 | GRM5 (0.56) | GRM5CYP3A4 | |
| SCHEMBL22619587 | 0.73 | GRM5 (0.48) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL4251839 | 0.73 | GRM5 (0.40) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL4254700 | 0.72 | GRM5 (0.44) | GRM5CYP1A2CYP3A4CACNA1CSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | claimed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | claimed |
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | GRM5 1/4885CYP1A2 3224/4885CYP3A4 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.